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Abstract
Background: The prevalence and frequency of oesophageal symptoms suggestive of a functional oesophageal disorder
according to the Rome IV criteria are unknown.
Objective: We aimed to describe the prevalence and risk factors for oesophageal symptoms compatible with functional
oesophageal disorders in the general population.
Methods: Data were analysed from a population-based online survey of 6300 individuals aged 18 years in the USA, UK and
Canada with equal demographic proportions across countries. Questions included the Rome IV diagnostic questionnaire,
demographics, medication, somatization, quality of life, and organic gastrointestinal (GI) disease. Multivariate analysis was
used to identify factors independently related to oesophageal symptoms.
Results: Data from 5177 participants (47.8% female; mean age 46.7 years) were available for analysis. Symptom prevalence
was 8.1% for globus, 6.5% for heartburn, 4.5% for dysphagia and 5.2% for chest pain, and 17.0% reported at least one
oesophageal symptom. Oesophageal symptoms were independently associated with younger age, female gender, previous
abdominal surgery and the presence of other functional GI disorders. Reporting oesophageal symptoms was associated with
reduced quality of life.
Conclusion: Oesophageal symptoms are common in the general population and important predictors include other func-
tional GI disorders, age and gender. Oesophageal symptoms are associated with poorer quality of life.
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Key summary
Current knowledge:
. Oesophageal symptoms result in high healthcare utilization and reduced quality of life.
. Functional oesophageal disorders are a common cause of symptoms but the prevalence in the general
population is largely unknown.
. No studies describing the overall frequency of oesophageal symptoms compatible with the Rome IV
criteria in the general population are available.
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Key findings of this study:
. We provide the first report of the population prevalence of the four symptoms used to define Rome IV
functional oesophageal disorders.
. Important predictors of these symptoms are the presence of non-oesophageal functional gastrointestinal
disorders, younger age, previous abdominal surgery and female gender.
Introduction
Oesophageal symptoms account for a significant pro-
portion of healthcare utilization, have a significant
impact on social and leisure activities, and result in
reduced quality of life (QoL).1,2 Furthermore, there is
an economic impact, both for the affected individual
and society in general, since work capacity may be
reduced in those affected by these symptoms.3,4 Many
of these individuals suffer from gastroesophageal reflux
disease (GERD), but a large proportion have an
oesophageal disorder that is part of the spectrum of
functional gastrointestinal (GI) disorders (FGIDs) cur-
rently defined by the Rome IV criteria.5 These oesopha-
geal disorders are characterized by chronic or
frequently recurring symptoms of presumed oesopha-
geal origin in the absence of identifiable structural,
inflammatory, motor or metabolic mechanism causes.
The prevalence of functional oesophageal disorders in
the general population is largely unknown, even
though several studies have described the prevalence
of non-cardiac chest pain,6 GERD7 and oesophageal
symptoms using different methodologies.8,9 Studies
that evaluate the overall frequency of oesophageal
symptoms compatible with functional oesophageal dis-
orders defined by the Rome IV criteria10 in the general
population and how they manifest clinically are
lacking.
We aimed to describe the prevalence of oesophageal
symptoms in the general population in three culturally
similar English-speaking countries and to identify risk
factors for symptoms compatible with functional
oesophageal disorders as defined by Rome IV criteria.10
We also aimed to assess the association of oesophageal




The study utilized data from an online survey of 6300
individuals aged 18 years in the USA, UK and
Canada (2100 in each country). Subjects were recruited
by a global market survey company (Qualtrics Inc.,
Provo, Utah) and asked to respond to a ‘health
survey’ with no specific mention of GI symptoms.
Written informed consent was obtained from subjects
prior to participation in the study and they were asked
to answer questions including the Rome IV diagnostic
questionnaire for adults, demographic data (age,
gender, ethnicity and living conditions), medical history
(GI diseases, history of abdominal surgery, medications
and healthcare utilization), QoL, non-GI symptoms
(somatization) and psychosocial factors.
By use of quota-based sampling, equal proportions
of sex (50/50%), age group (40% age 18–39, 40% age
40–64 and 20% age 65þ) and education distributions
(maximum 30% of the study population with a college
degree or equivalent) across countries was ensured.
Inconsistent responders (identified by repeated symp-
tom questions) and responders who answered in a
random manner were eliminated from the data set in
a rigorous process, as were individuals who completed
the survey unreasonably quickly. Details have been
reported elsewhere11–14 (comparability in the supple-
ment12). Before data collection started, the study was
reviewed by the ethical committee in North Carolina,
USA, and was approved but was deemed not to for-
mally require an ethical approval as the subjects were
completely anonymous. The study protocol conforms
to the ethical guidelines of the 1975 Declaration of
Helsinki.
Oesophageal symptoms and Rome IV diagnosis
The prevalence and frequency of oesophageal symp-
toms in the past 3 months, and their consistency with
a diagnosis of a functional oesophageal disorder, were
assessed based on responses to the Rome IV diagnostic
questionnaire.14 The Rome IV functional oesophageal
disorders are: functional chest pain, functional heart-
burn, reflux hypersensitivity, globus and functional
dysphagia.10 As combinations of endoscopy, pH moni-
toring and oesophageal manometry are required for the
clinical diagnosis of oesophageal disorders, we were
able to describe oesophageal symptoms compatible
with functional oesophageal disorders only.10 We
used the minimum diagnostic frequency cut-off for
each of the oesophageal symptoms, used to define the
functional oesophageal disorders according to Rome
IV, to classify symptoms as present (at least weekly
for dysphagia, chest pain and globus, and twice
weekly for heartburn) or not.10 However, we also
described the frequency of survey responders with
symptom constellations compatible with a functional
oesophageal disorder according to the Rome IV
definition.
Somatization and QoL
QoL during the month prior to the survey was assessed
by the Short Form (SF)-8 questionnaire.15 The SF-8 is
similar to the SF-36v2 16 but is condensed to eight items,
one for each domain. A physical component summary
(PCS) score and a mental component summary (MCS)
score can be calculated from the SF-8 results. The PCS
score ranges from 10–67 (10 is very poor and 67 excellent
QoL). The MCS score ranges from 8–70 (8 is very poor
and 70 excellent QoL).15
Somatization, or non-GI symptom severity, was
assessed with the Patient Health Questionnaire
(PHQ)-12,17 which is a shortened version of the PHQ-
15,18 but with the three questions on GI symptoms
excluded. The questionnaire assesses how bothersome
12 non-GI somatic symptoms were in the past month,
each rated on a three-point scale (0¼ ‘not bothered
at all’, 1¼ ‘bothered a little’ and 2¼ ‘bothered a lot’).
The maximum score is 24 points.
Statistics
The Mann–Whitney U test or Students t-test was used
for group comparisons for continuous variables. 2
analyses were used for dichotomous variables. In
order to identify variables that were independently
associated with specific oesophageal symptoms, we cal-
culated Spearman correlation coefficients between the
specific oesophageal symptoms and other variables in
the survey. Variables with a significance level of p 0.1
in the univariate analyses were then entered into a
multivariate analysis (logistic regression) and variables
with a p-value of< 0.05 in that analysis were considered
significant. We either excluded variables with
significant overlap or merged them into a single vari-
able (such as presence of an FGID instead of several
different subgroups of FGIDs). We also excluded vari-
ables in the multivariate analysis not considered to be
risk factors for developing an oesophageal symptom,
but were more likely to reflect the effect of having
one, such as being treated with a proton pump inhibitor
or visiting a doctor.
The number of different regions of the GI tract
where the patient had FGIDs according to the anatom-
ical groupings of diagnoses in the ROME IV criteria,
excluding the oesophagus (maximum three: anorectal,
gastroduodenal and bowel disorder), was used for fur-
ther analyzes.
Individuals who had previously been diagnosed by a
doctor with GERD or acid reflux were excluded from
the primary study sample. However, we also re-ran our
analyses with these individuals included.
We also tested the hypothesis that an increasing
frequency of any oesophageal symptom would be asso-
ciated with worsening QoL and more severe non-GI
somatic symptoms (PHQ-12), by using analysis of vari-
ance with linear contrast analysis to look for a linear
trend, with effect sizes demonstrated as partial eta
squared (Z2); small effect size 0.01, medium effect size
0.06 and large effect size 0.14).19 Statistical analyses
were conducted using the IBM SPSS Statistics soft-
ware, version 21 for Windows.
Results
Population
We included data from 5177 participants in the primary
analysis (Figure 1), after excluding 369 inconsistent
responders (6%) and 754 who reported a previous
GERD diagnosis (12%). The mean age was 46.7








Figure 1. Flow chart of study selection.
GERD: gastroesophageal reflux disease.
Prevalence of symptoms
Globus was the most prevalent oesophageal symptom
with 8.1% (n¼ 420), followed by heartburn 6.5%
(n¼ 334), chest pain 5.2% (n¼ 269) and dysphagia
4.5% (n¼ 233) (Figure 2). In all, 17.0% (n¼ 881) had
at least one oesophageal symptom. Of these, 621
(12.0%) had only one symptom, 170 (3.3%) two,
65 (1.3%) three and 25 (0.5%) had all four symptoms.
The prevalence of globus (USA 8.0%, Canada 8.9%
and UK 7.4%; p¼ 0.24) and chest pain (USA 3.6%,
Canada 2.6% and UK 2.7%; p¼ 0.16) did not differ
among the three countries. However, heartburn (USA
8.9%, Canada 6.0% and UK 4.6%; p< 0.001) and dys-
phagia (USA 6.0%, Canada 3.5% and UK 4.1%;
p¼ 0.001) showed a different distribution between the
countries with the highest prevalence rate in the USA.
The prevalence of symptoms that clustered in constel-
lations with a symptom duration consistent with
oesophageal disorders as defined by the Rome IV cri-
teria10 was 1% for globus, 3.2% for functional dyspha-
gia, 0.7% for reflux hypersensitivity, 0.8% for
functional chest pain and 1.1% for functional
heartburn.
Factors associated with oesophageal symptoms
Factors associated with oesophageal symptoms in the
univariate analysis included younger age, female sex,
previous abdominal surgeries, overlap with other
FGIDs, and having other medical conditions and
non-GI physical symptoms. However, in the multivari-
ate analysis, only symptoms consistent with other
FGIDs (higher risk for all oesophageal symptoms), pre-
vious abdominal surgery (higher risk for all symptoms
but chest pain), age (younger age associated with a
higher risk for all symptoms), female gender (higher
risk for all symptoms but heartburn) and coeliac
disease (higher risk for chest pain) were independent
contributors to the variance in having oesophageal
symptoms (Table 1). When individuals with GERD
were included in re-analyses, GERD was a significant
predictor for all oesophageal symptoms; chest pain
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Figure 2. Prevalence of oesophageal symptoms.
(odds ratio (OR) 2.82), dysphagia (OR 2.47), globus
(OR 1.73) and heartburn (OR 4.48).
With increasing numbers of regions with an FGID, a
gradual increased in the proportion of subjects report-
ing oesophageal symptoms could be detected (p< 0.001
for all symptoms, Figure 3).
We compared the characteristics of subjects with at
least one of the oesophageal symptoms with subjects
without oesophageal symptoms (Table 2). Those with
oesophageal symptoms were younger, had higher rates
of coeliac disease, inflammatory bowel disease and
peptic ulcer disease, and reported using multiple medi-
cations more often. Participants with oesophageal
symptoms also reported more healthcare utilization
and had lower QoL scores.
Oesophageal symptoms, QoL, healthcare
utilization and non-GI symptoms
The impact of oesophageal symptoms on QoL was
related to the frequency of symptoms. A statistically
significant linear trend in declining QoL was seen
with increasing frequency of each of the oesophageal
symptoms, with small to medium effect sizes (partial
Z2¼ 0.034–0.091, Table 3). Low scores in both the
PCS and the MCS were related to globus, chest pain,
heartburn and dysphagia (p< 0.001 for all, Mann–
Whitney U test).
In our subject sample, 965 (18.6%) of all responders
had seen a doctor because of concerns with their GI
health problems. This percentage was significantly
higher for individuals with any of the oesophageal
symptoms compared with subjects without oesophageal
symptoms: 33 vs 17% for those with globus, 31 vs 18%
for heartburn, 39.5 vs 18% for dysphagia and 37 vs
18% for those with chest pain (p< 0.001 for all).
The median PHQ-12 score in our cohort was 4
(range 0–24). In contrast to QoL scores, there were
no significant linear trend effects between the frequency
of any of the oesophageal symptoms and PHQ-12
scores (Table 3).
Discussion
In this study, we present data on oesophageal symp-
toms in a large representative sample of the general
population of adults in three English-speaking coun-
tries with comparable age, gender and educational
distributions. Symptom prevalence ranged between
4.5–8.1% depending on the symptom, and a prevalence
of symptom constellations compatible with a diagnosis
of a functional oesophageal disorder ranged from
0.8–3.2% depending on the disorder. The most import-
ant factors associated with oesophageal symptoms were



































































































































































































































































































































































































































































































































































































































































































































































































































































































































(n¼ 881; 17%) p-value*
Demographics
Mean age (SD) 46.6 (17.2) 47.3 (17.4) 43.5 (16.1) <0.001
Female 2477 (47.4%) 2038 (47.4%) 439 (49.8%) 0.19
White ethnicity 3695 (71.4%) 3049 (71%) 646 (73.3%) 0.18
Other conditions
Diabetes 528 (10.2%) 449 (10.5%) 71 (9.0%) 0.18
Coeliac disease 24 (0.5%) 14 (0.3%) 10 (1.1%) 0.001
Irritable bowel disease 60 (1.2%) 43 (1.0%) 17 (1.9%) 0.019
Peptic ulcer 61 (1.2%) 43 (1.0%) 18 (2.0%) 0.009
Medication taken at least once weekly
Gastrointestinal-specific medication
(except acid suppressant)
558 (10.8%) 340 (7.9%) 218 (24.7%) <0.001
Acid suppressive medication 613 (11.8%) 328 (7.6%) 285 (32.3%) <0.001
Analgesics 1352 (26.1%) 1002 (23.3%) 350 (39.7%) <0.001
Psychotropic medicine 726 (14%) 511 (11.9%) 215 (24.4%) <0.001
Complementary medicine 356 (6.9%) 269 (6.3%) 87 (9.9%) <0.001
Any of the above 2217 (42.8%) 1631 (38%) 586 (66.5%) <0.001
Healthcare utilization
More than one annual healthcare visit 2803 (54.1%) 2232 (52%) 571 (64.8%) <0.001
Symptom scores
Mean PHQ-12 somatization score (SD) 4.78 (3.8) 4.77 (3.8) 4.80 (3.9) 0.86
Mean SF-8 MCS Score 49.4 (10.8) 50.5 (10.0) 43.5 (12.3) <0.001
Mean SF-8 PCS Score 50.0 (9.3) 50.8 (8.7) 45.6 (10.4) <0.001
*p-value is the comparison between subjects with and without oesophageal symptoms.
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Figure 3. Relationship between the number of regions with functional gastrointestinal disorders (oesophageal disorders excluded) in
patients and the corresponding percentage of subjects reporting an oesophageal symptom, p< 0.001 for all.
FGID: functional gastrointestinal disorders.
FGIDs. Importantly, having oesophageal symptoms
was clearly associated with reduced physical and
mental QoL, and increased healthcare utilization.
In this study, the strongest risk factor for reporting
oesophageal symptoms was overlap with GI symptoms
compatible with other FGIDs, which is consistent with
prior research that showed that oesophageal symptoms
suggestive of GERD are excessively common in
patients with irritable bowel syndrome (IBS).8
Although the frequency varies widely between studies,
about a fourfold increase is seen overall. The wide vari-
ability in frequency estimates is most likely due to dif-
ferences in diagnostic criteria of GERD and the
different minimum frequency of symptoms required
for the diagnosis of GERD-like symptoms.20
Dyspepsia21 and globus20 have also been shown to
overlap with GERD symptoms, while globus has been
shown to overlap with IBS. However, these studies had
small sample sizes and were likely to have problems
with selection bias. However, there are some more
recent studies that have shown that FGIDs commonly
overlap.22–24 The cause for this overlap between
oesophageal symptoms and FGIDs in other GI tract
regions is not known, but a generalized visceral hyper-
sensitivity in the GI tract,25,26 disturbed brain–gut
interactions,27 and comorbid psychological disturb-
ances and somatization12,28 may explain this overlap.
Some other associations and also lack of associ-
ations seen in this study were noteworthy. Previous
abdominal surgery was found to be associated with
symptoms compatible with a functional oesophageal
disorder, which is in line with previous studies that
have reported that abdominal surgery can contribute
to symptoms in FGIDs, in particular for bowel
disorders.29,30 Somatization has also been found to be
associated with increased severity of GI symptoms,
including oesophageal symptoms, in previous stu-
dies.31,32 However, this could not be confirmed in the
present study. The reason for this is unclear. Dysphagia
and heartburn were significantly more common in the
USA than in the UK and Canada, and patients from
USA also reported more oesophageal symptoms over-
all. A possible explanation could be the significantly
higher prevalence of obesity in the USA compared to
the UK and Canada.33 However, we did not have
access to body mass index data on the study partici-
pants and this could not be correlated with symptoms.
In our study, we found that suffering from oesophageal
symptoms is associated with reduced QoL, increased
healthcare consumption and some non-GI conditions
such as previous abdominal surgery, peptic ulcer dis-
ease and coeliac disease. This is, to some extent, also
consistent with other previous studies.1,2,6,22
Our study has several strengths. We included
patients from three native English-speaking countries
with similar demographics, to minimize language and
demographic effects. To date, validated translations of
the Rome IV questionnaire have not been available for
global use. We used the entire Rome IV diagnostic ques-
tionnaire, allowing us to assess the impact of FGIDs in
multiple regions of the GI tract. In addition, a broad
range of questions regarding other important lifestyle,
medical and general health factors were included in the
survey and used in our analyses to further understand
associations with oesophageal symptoms.
Our study also has limitations. It was an online
survey with self-reported symptoms, and no objective
evaluation of whether an organic disease could explain
the symptoms was present. The new Rome IV criteria
require an endoscopic evaluation, 24-hour pH monitor-
ing and manometry to make a diagnosis of a functional
oesophageal disorder, which was unavailable in our
cohort.10 Even though we tried to include a represen-
tative cohort from the general population, some sectors
of the population were less likely to be represented in
the study population. People without internet access
and non-English speaking minorities were unable to
participate for obvious reasons. However, as we have
reported elsewhere in detail, our survey samples in each
of the countries were representative of their respective
national adult populations.12 Finally, another limita-
tion is that most of the symptoms that we analysed
could have been caused by GERD.6 Even though we
excluded participants who had previously been diag-
nosed with GERD, it is possible that some of the symp-
toms included in our results were caused by
undiagnosed GERD.
In this study, we have provided the first report of the
population prevalence of the four symptoms used to
Table 3. Partial Z2 in symptom frequency, quality of life and
Patient Health Questionnaire-12.
Variable p-value Partial Z2
Globus SF-8 PCS <0.001 0.034
Globus SF-8 MCS <0.001 0.069
Dysphagia SF-8 PCS <0.001 0.048
Dysphagia SF-8 MCS <0.001 0.069
Chest pain SF-8 PCS <0.001 0.060
Chest pain SF-8 MCS <0.001 0.092
Heart burn SF-8 PCS <0.001 0.036
Heart burn SF-8 MCS <0.001 0.051
Globus PHQ-12 0.26 0.002
Dysphagia PHQ-12 0.051 0.003
Chest pain PHQ-12 0.752 0.001
Heart burn PHQ-12 0.41 0.002
PCS: physical component summary; MCS: mental component summary;
SF-8: Short Form-8; PHQ-12: Patient Health Questionnaire-12.
define Rome IV functional oesophageal disorders and
identified some of the important predictors of these
symptoms. We also demonstrated the relevance of
these symptoms from the patients’ and societies’ per-
spective, since they are associated with substantial
healthcare consumption and reduced QoL. Further stu-
dies are needed in order to confirm these results in other
populations.
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